GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company's proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos de Lisboa in Libson, Portugal.
"Our data being presented at ESID validates the therapeutic potential of our novel recombinant hyperimmune gammaglobulin, generated by our Surge platform, to deliver increased potency and antigen specificity relative to existing plasma-derived products," said David Johnson, Ph.D., chief executive officer. "We are now in the process of evaluating efficacy in additional studies and look forward to moving this program toward the clinic to help immune deficient patients fight harmful pathogens, including bacterial infections."
Details of GigaGen's ESID 2018 presentation are as follows:
Abstract Number: 288
View original content to download multimedia:http://www.prnewswire.com/news-releases/gigagen-to-present-data-on-recombinant-hyperimmune-gammaglobulin-at-the-18th-biennial-meeting-of-the-european-society-for-immunodeficiencies-300738449.html
SOURCE GigaGen Inc.